Amneal, Zambon Biotech Enter Exclusive European Licensing Agreement for Parkinson’s Disease Medication
IPX203—an oral formulation carbidopa/levodopa extended-release capsules —would expand Zambon’s neurology portfolio.
Amneal Pharmaceuticals, Inc. has entered into an exclusive licensing agreement with Zambon Biotech SA, a chemical pharmaceutical company, for IPX203 in the European Union, United Kingdom, and Switzerland. IPX203 is an oral formulation of carbidopa/levodopa (CD/LD) extended-release capsules that treats Parkinson’s disease (PD); the manufacturer is seeking regulatory approval of IPX203 in Europe, and is currently under review by the FDA.
The pharma company’s specialty lies in the European neurology space—with its launch and commercialization of XADAGO (safinamide) as an LD add-on for PD treatment—so if approved, IPX203 is expected to nicely blend with its current portfolio.
“Zambon Biotech’s mission is to build a long-term pipeline of innovative medicines that make patients’ lives better. Given our group’s capabilities in commercialization and our existing footprint in neurology, particularly Parkinson’s, we are pleased to partner with Amneal to bring IPX203 to Parkinson’s patients in Europe,” said Frank Weber, Zambon Biotech’s CEO.
As for Amneal, it has high aspirations in the battle for PD treatment.
“We believe IPX203 can improve the lives of the more than 10 million people worldwide living with Parkinson’s disease. It has been a strategic goal of Amneal to ensure that not only US patients, but also Parkinson’s patients worldwide have access to our products,” noted Chirag and Chintu Patel, Amneal’s co-CEOs. “Zambon, a family-owned business with whom we share a long-term vision and commitment toward patient communities, is the right partner to extend the reach of IPX203 to Europe.”
Reference
Amneal Enters into Exclusive European Licensing Agreement with Zambon Biotech for IPX203. Amneal. News release. February 27, 2024. Accessed February 29, 2024. https://investors.amneal.com/news/press-releases/press-release-details/2024/Amneal-Enters-into-Exclusive-European-Licensing-Agreement-with-Zambon-Biotech-for-IPX203/default.aspx
Understanding the FDA's Exemption for DSCSA Compliance
November 12th 2024In the quest for achieving full traceability, the exemption applies to certain trading partners under the Act, and postpones enforcement of final compliance requirements while acknowledging progress and ongoing challenges.
